Evidence map›Paper›PMID 39001992›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2024

Changes in skeletal muscle function during chemotherapy and related factors in patients with acute leukemia.

Yusuke Terao, Yasuhide Nakayama, Masahiro Abo, Yuhei Otobe, Mizue Suzuki, Iwao Kojima, Shu Tanaka, Shingo Koyama, Haruhiko Kusumi, Minoru Yamada

Abstract read
PubMed Publisher
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yusuke TeraoDepartment of Rehabilitation Medicine, The Jikei University School of Medicine Hospital, Tokyo, Japan. t-yusuke@jikei.ac.jp.
Yasuhide NakayamaDepartment of Rehabilitation Medicine, The Jikei University School of Medicine Hospital, Tokyo, Japan.
Masahiro AboDepartment of Rehabilitation Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Yuhei OtobeSchool of Medicine, Department of Rehabilitation Science, Physical Therapy Course, Osaka Metropolitan University, Osaka, Japan.
Mizue SuzukiFaculty of Allied Health Sciences, Yamato University, Osaka, Japan.
Iwao KojimaGraduate School of Comprehensive Human Sciences, University of Tsukuba, Tokyo, Japan.
Shu TanakaGraduate School of Comprehensive Human Sciences, University of Tsukuba, Tokyo, Japan.
Shingo KoyamaGraduate School of Comprehensive Human Sciences, University of Tsukuba, Tokyo, Japan.
Haruhiko KusumiGraduate School of Comprehensive Human Sciences, University of Tsukuba, Tokyo, Japan.
Minoru YamadaFaculty of Human Sciences, University of Tsukuba, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionSkeletal muscle function is an important prognostically relevant indicator in patients with acute leukemia (AL), but skeletal dysfunction during chemotherapy is not well understood. This study aimed to investigate the factors that influence changes in skeletal muscle function from before the start of chemotherapy to before allogeneic hematopoietic stem cell transplantation (allo-HSCT).

methodsThis was a retrospective cohort study that included 90 patients with AL who underwent chemotherapy before transplantation to perform allo-HSCT (men, 67.3%; median age, 53 years). The outcome measure was defined as changes in skeletal muscle function from before chemotherapy to before allo-HSCT, and was assessed by measuring the psoas muscle index (PMI) as skeletal muscle quantity and computed tomography values (CTV) as skeletal muscle quality using a computed tomography scanner. We examined the differences in PMI and CTV before chemotherapy and allo-HSCT, and the factors associated with changes in PMI.

resultThe mean PMI for before chemotherapy and allo-HSCT were 4.6 ± 1.4 cm

conclusionWe found that skeletal muscle quantity decreased during chemotherapy in patients with AL and was influenced by male sex and older age. TRIAL REGISTRATION NUMBER: TRIAL REGISTRATION NUMBER: 34-096(11,243). Date of registration: September 11, 2023.

Indexed as

Hematopoietic Stem Cell TransplantationMuscle, SkeletalAcute DiseaseAdultAgedAntineoplastic AgentsCohort StudiesFemaleHumansLeukemiaLeukemia, Myeloid, AcuteMaleMiddle AgedPsoas MusclesRetrospective StudiesTomography, X-Ray ComputedAntineoplastic AgentsAcute leukemiachemotherapySkeletal muscle quantity

Identifiers

PMID39001992

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.